Cercador de Publicacions

La producció científica dels nostres investigadors i investigadores és molt elevada. L'any 2022 es van publicar 1.629 articles a revistes científiques amb un factor d'impacte global que va superar els 15.000 punts.

Basis for the interpretation of noninferiority studies: considering the ROCKET-AF, RE-LY, and ARISTOTLE studies.

PMID: 24863590
Revista: REVISTA ESPANOLA DE CARDIOLOGIA
Any: 2014
Referència: Rev Esp Cardiol. 2014 Jun;67(6):432-5. doi: 10.1016/j.rec.2013.10.018. Epub 2014 Feb 26.
Factor d'impacte: 3.342
Tipus de publicació: Editorial en revista nacional
Autors: Ferreira-Gonzalez, Ignacio et al.
DOI: 10.1016/j.rec.2013.10.018

Basis for the interpretation of noninferiority studies: considering the ROCKET-AF, RE-LY, and ARISTOTLE studies.

PMID: 24863590
Revista: REVISTA ESPANOLA DE CARDIOLOGIA
Any: 2014
Referència: Rev Esp Cardiol. 2014 Jun;67(6):432-5. doi: 10.1016/j.rec.2013.10.018. Epub 2014 Feb 26.
Factor d'impacte:
Tipus de publicació: Editorial en revista nacional
Autors: Ferreira-Gonzalez, Ignacio et al.
DOI: 10.1016/j.rec.2013.10.018

BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

PMID: 24686337
Revista: AUTOPHAGY
Any: 2014
Referència: Autophagy. 2014 May 1;10(5):889-900. doi: 10.4161/auto.28286. Epub 2014 Mar 26.
Factor d'impacte: 11.423
Tipus de publicació: Article en revista internacional
Autors: Bove, Jordi, Martinez-Vicente, Marta , Dehay, Benjamin, Perier, Celine, Recasens, Ariadna, Bombrun, Agnes, Antonsson, Bruno, Vila, Miquel et al.
DOI: 10.4161/auto.28286

BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

PMID: 24686337
Revista: Autophagy
Any: 2014
Referència: Autophagy. 2014 May 1;10(5):889-900. doi: 10.4161/auto.28286. Epub 2014 Mar 26.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Antonsson, Bruno; Bombrun, Agnes; Bove, Jordi; Dehay, Benjamin; Martinez-Vicente, Marta ; Perier, Celine; Recasens, Ariadna; Vila, Miquel et al.
DOI: 10.4161/auto.28286

Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.

PMID: 25118611
Revista: INT J PEPT RES THER
Any: 2014
Referència: Int Urol Nephrol. 2014 Oct;46(10):1983-95. doi: 10.1007/s11255-014-0800-4. Epub 2014 Aug 14.
Factor d'impacte: 1.293
Tipus de publicació: Article en revista internacional
Autors: Portoles, Jose, Calls, Jordi, Martinez-Castelao, Alberto, Munar, Maria Antonia, Segarra, Alfonso, Cases, Aleix et al.
DOI: 10.1007/s11255-014-0800-4

Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.

PMID: 25118611
Revista: International Journal of Peptide Research and Therapeutics
Any: 2014
Referència: Int Urol Nephrol. 2014 Oct;46(10):1983-95. doi: 10.1007/s11255-014-0800-4. Epub 2014 Aug 14.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Calls, Jordi; Cases, Aleix; Martinez-Castelao, Alberto; Munar, Maria Antonia; Portoles, Jose; Segarra, Alfonso et al.
DOI: 10.1007/s11255-014-0800-4

Best approach for posterior mediastinal goiter removal: transcervical incision and lateral thoracotomy.

PMID: 24239133
Revista: ARCH BRONCONEUMOL
Any: 2014
Referència: Arch Bronconeumol. 2014 Jun;50(6):255-7. doi: 10.1016/j.arbres.2013.09.009. Epub 2013 Nov 12.
Factor d'impacte: 1.816
Tipus de publicació: Carta o abstract
Autors: Olsina Kissle, Jorge Juan, Ojanguren Arranz, Inigo, Santamaria Gomez, Maite, Ros Lopez, Susana, Baena Fustegueras, Juan Antonio, Ojanguren Arranz, Amaya et al.
DOI: 10.1016/j.arbres.2013.09.009

Best approach for posterior mediastinal goiter removal: transcervical incision and lateral thoracotomy.

PMID: 24239133
Revista: ARCHIVOS DE BRONCONEUMOLOGIA
Any: 2014
Referència: Arch Bronconeumol. 2014 Jun;50(6):255-7. doi: 10.1016/j.arbres.2013.09.009. Epub 2013 Nov 12.
Factor d'impacte:
Tipus de publicació: Carta o abstract
Autors: Baena Fustegueras, Juan Antonio; Ojanguren Arranz, Amaya; Ojanguren Arranz, Inigo; Olsina Kissle, Jorge Juan; Ros Lopez, Susana; Santamaria Gomez, Maite et al.
DOI: 10.1016/j.arbres.2013.09.009

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial.

PMID: 24637997
Revista: J CLIN ONCOL
Any: 2014
Referència: J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.
Factor d'impacte: 17.96
Tipus de publicació: Assaig clínic
Autors: Pujade-Lauraine, Eric, Hilpert, Felix, Weber, Beatrice, Reuss, Alexander, Poveda, Andres, Kristensen, Gunnar, Sorio, Roberto, Vergote, Ignace, Witteveen, Petronella, Bamias, Aristotelis et al.
DOI: 10.1200/JCO.2013.51.4489

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial.

PMID: 24637997
Revista: JOURNAL OF CLINICAL ONCOLOGY
Any: 2014
Referència: J Clin Oncol. 2014 May 1;32(13):1302-8. doi: 10.1200/JCO.2013.51.4489. Epub 2014 Mar 17.
Factor d'impacte:
Tipus de publicació: Assaig clínic
Autors: Bamias, Aristotelis; Bollag, David; Follana, Philippe; Hilpert, Felix; Kristensen, Gunnar; Mirza, Mansoor Raza; Oaknin, Ana; Pereira, Deolinda; Poveda, Andres; Pujade-Lauraine, Eric et al.
DOI: 10.1200/JCO.2013.51.4489

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

PMID: 25273342
Revista: LANCET ONCOL
Any: 2014
Referència: Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28.
Factor d'impacte: 24.725
Tipus de publicació: Article en revista internacional
Autors: von Minckwitz, Gunter, Puglisi, Fabio, Cortes, Javier, Vrdoljak, Eduard, Marschner, Norbert, Zielinski, Christoph, Villanueva, Cristian, Romieu, Gilles, Lang, Istvan, Ciruelos, Eva et al.
DOI: 10.1016/S1470-2045(14)70439-5

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

PMID: 25273342
Revista: LANCET ONCOLOGY
Any: 2014
Referència: Lancet Oncol. 2014 Oct;15(11):1269-78. doi: 10.1016/S1470-2045(14)70439-5. Epub 2014 Sep 28.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Ciruelos, Eva; Cortes, Javier; de Ducla, Sabine; De Laurentiis, Michele; Freudensprung, Ulrich; Gligorov, Joseph; Lang, Istvan; Marschner, Norbert; Puglisi, Fabio; Romieu, Gilles et al.
DOI: 10.1016/S1470-2045(14)70439-5

Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon).

PMID: 24958752
Revista: CIRCULATION
Any: 2014
Referència: Circulation. 2014 Jun 24;129(25):2691-704. doi: 10.1161/CIRCULATIONAHA.113.007851.
Factor d'impacte: 14.948
Tipus de publicació: Revisió en revista internacional
Autors: Isselbacher, Eric M, Enriquez-Sarano, Maurice, Sundt, Thoralf M 3rd, Pibarot, Philippe, Evangelista, Artur, Milewicz, Dianna M, Body, Simon C, Lancellotti, Patrizio, Benson, D Woodrow, Limongelli, Giuseppe et al.
DOI: 10.1161/CIRCULATIONAHA.113.007851

Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon).

PMID: 24958752
Revista: CIRCULATION
Any: 2014
Referència: Circulation. 2014 Jun 24;129(25):2691-704. doi: 10.1161/CIRCULATIONAHA.113.007851.
Factor d'impacte:
Tipus de publicació: Revisió en revista internacional
Autors: Anavekar, Nandan; Benson, D Woodrow; Bissell, Malenka M; Body, Simon C; Bosse, Yohan; Bossone, Eduardo; Della Corte, Alessandro; Enriquez-Sarano, Maurice; Evangelista, Artur; Isselbacher, Eric M et al.
DOI: 10.1161/CIRCULATIONAHA.113.007851

Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.

PMID: 24833043
Revista: BRIT J CLIN PHARMACO
Any: 2014
Referència: Br J Clin Pharmacol. 2014 Nov;78(5):970-80. doi: 10.1111/bcp.12421.
Factor d'impacte: 3.688
Tipus de publicació: Guia clínica
Autors: Rojas, Santiago, Herance, Jose-Raul, Trampal, Carlos, Labeaga, Luis, Valiente, Roman, Bullich, Santiago, Martin, Soraya, Perez, Marta, Menoyo, Esther, Farre, Magi et al.
DOI: 10.1111/bcp.12421

Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.

PMID: 24833043
Revista: BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Any: 2014
Referència: Br J Clin Pharmacol. 2014 Nov;78(5):970-80. doi: 10.1111/bcp.12421.
Factor d'impacte:
Tipus de publicació: Guia clínica
Autors: Bullich, Santiago; Farre, Magi; Herance, Jose-Raul; Labeaga, Luis; Martin, Soraya; Menoyo, Esther; Papaseit, Esther; Perez, Marta; Perez-Mana, Clara; Rojas, Santiago et al.
DOI: 10.1111/bcp.12421

[Biologic therapy in idiopathic inflammatory myopathy].

PMID: 24393419
Revista: MED CLIN-BARCELONA
Any: 2014
Referència: Med Clin (Barc). 2014 Sep 15;143(6):275-80. doi: 10.1016/j.medcli.2013.11.009. Epub 2014 Jan 3.
Factor d'impacte: 1.252
Tipus de publicació: Revisió en revista nacional
Autors: Selva-O'Callaghan, Albert, Ramos Casals, Manel, Grau Junyent, Josep M et al.
DOI: 10.1016/j.medcli.2013.11.009

[Biologic therapy in idiopathic inflammatory myopathy].

PMID: 24393419
Revista: MEDICINA CLINICA
Any: 2014
Referència: Med Clin (Barc). 2014 Sep 15;143(6):275-80. doi: 10.1016/j.medcli.2013.11.009. Epub 2014 Jan 3.
Factor d'impacte:
Tipus de publicació: Revisió en revista nacional
Autors: Grau Junyent, Josep M; Ramos Casals, Manel; Selva-O'Callaghan, Albert et al.
DOI: 10.1016/j.medcli.2013.11.009

Biological insights from 108 schizophrenia-associated genetic loci.

PMID: 25056061
Revista: NATURE
Any: 2014
Referència: Nature. 2014 Jul 24;511(7510):421-7. doi: 10.1038/nature13595. Epub 2014 Jul 22.
Factor d'impacte: 42.351
Tipus de publicació: Article en revista internacional
Autors: Bevilacqua, Elizabeth, Bigdeli, Tim B, Black, Donald W, Bruggeman, Richard, Buccola, Nancy G, Buckner, Randy L, Byerley, William, Cahn, Wiepke, Cai, Guiqing, Campion, Dominique et al.
DOI: 10.1038/nature13595

Biological insights from 108 schizophrenia-associated genetic loci.

PMID: 25056061
Revista: NATURE
Any: 2014
Referència: Nature. 2014 Jul 24;511(7510):421-7. doi: 10.1038/nature13595. Epub 2014 Jul 22.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Adolfsson, Rolf; Agartz, Ingrid; Agerbo, Esben; Albus, Margot; Alexander, Madeline; Amin, Farooq; Andreassen, Ole A; Ausrele Kucinskiene, Zita; Bacanu, Silviu A; Begemann, Martin et al.
DOI: 10.1038/nature13595

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

PMID: 25332247
Revista: J CLIN ONCOL
Any: 2014
Referència: J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20.
Factor d'impacte: 17.96
Tipus de publicació: Article en revista internacional
Autors: Baselga, Jose, Cortes, Javier, Im, Seock-Ah, Clark, Emma, Ross, Graham, Kiermaier, Astrid, Swain, Sandra M et al.
DOI: 10.1200/JCO.2013.54.5384

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

PMID: 25332247
Revista: JOURNAL OF CLINICAL ONCOLOGY
Any: 2014
Referència: J Clin Oncol. 2014 Nov 20;32(33):3753-61. doi: 10.1200/JCO.2013.54.5384. Epub 2014 Oct 20.
Factor d'impacte:
Tipus de publicació: Article en revista internacional
Autors: Baselga, Jose; Clark, Emma; Cortes, Javier; Im, Seock-Ah; Kiermaier, Astrid; Ross, Graham; Swain, Sandra M et al.
DOI: 10.1200/JCO.2013.54.5384

Biomarkers in multiple sclerosis: an update for 2014.

PMID: 24915032
Revista: REV NEUROLOGIA
Any: 2014
Referència: Rev Neurol. 2014 Jun 16;58(12):553-70.
Factor d'impacte: 0.926
Tipus de publicació: Revisió en revista nacional
Autors: Vidal-Jordana, Angela, Fernandez-Sanchez, Victoria E, Alvarez-Cermeno, Jose C, Izquierdo, Guillermo, Arroyo-Gonzalez, Rafael, Rodriguez-Antiguedad, Alfredo, Casanova-Estruch, Bonaventura, Montalban, Xavier, Llufriu, Sara, Rovira, Alex et al.
DOI:

Biomarkers in multiple sclerosis: an update for 2014.

PMID: 24915032
Revista: REVISTA DE NEUROLOGIA
Any: 2014
Referència: Rev Neurol. 2014 Jun 16;58(12):553-70.
Factor d'impacte:
Tipus de publicació: Revisió en revista nacional
Autors: Alvarez-Cermeno, Jose C; Arroyo-Gonzalez, Rafael; Casanova-Estruch, Bonaventura; Fernandez, Oscar; Fernandez-Sanchez, Victoria E; Izquierdo, Guillermo; Llufriu, Sara; Martin, Roland; Montalban, Xavier; Rodriguez-Antiguedad, Alfredo et al.
DOI:

Publicacions

Cercador de Publicacions

Basis for the interpretation of noninferiority studies: considering the ROCKET-AF, RE-LY, and ARISTOTLE studies.

Basis for the interpretation of noninferiority studies: considering the ROCKET-AF, RE-LY, and ARISTOTLE studies.

BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

BAX channel activity mediates lysosomal disruption linked to Parkinson disease.

Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.

Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study.

Best approach for posterior mediastinal goiter removal: transcervical incision and lateral thoracotomy.

Best approach for posterior mediastinal goiter removal: transcervical incision and lateral thoracotomy.

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial.

Bevacizumab Combined With Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: The AURELIA Open-Label Randomized Phase III Trial.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial.

Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon).

Bicuspid aortic valve: identifying knowledge gaps and rising to the challenge from the International Bicuspid Aortic Valve Consortium (BAVCon).

Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.

Bilastine vs. hydroxyzine: occupation of brain histamine H1 -receptors evaluated by positron emission tomography in healthy volunteers.

[Biologic therapy in idiopathic inflammatory myopathy].

[Biologic therapy in idiopathic inflammatory myopathy].

Biological insights from 108 schizophrenia-associated genetic loci.

Biological insights from 108 schizophrenia-associated genetic loci.

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.

Biomarkers in multiple sclerosis: an update for 2014.

Biomarkers in multiple sclerosis: an update for 2014.

Patronat:

Col·labora:

Acreditacions: